Vimarsana
Biggest News Aggregation in the World

Clin Pract News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clin Pract. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clin Pract Today - Breaking & Trending Today

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting - Vimarsana News

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Published: April 24, 2024

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a...

Source: prnewswire.com
Related Topics:
United StatesComunidad Autonoma De CatalunaAntonio AlcarazAhsan ArozullahEuropean UnionDrug AdministrationEuropean Association Of UrologyEuropean CommissionDepartment Of UrologyAmerican Society Of Clinical OncologyUniversity Hospital Clinic Of BarcelonaCommittee For Medicinal Products Human UseEuropean Medicines AgencyAstellas Pharma IncPrnewswire Astellas Pharma IncHead Of Oncology DevelopmentEuropean AssociationUniversity Hospital ClinicEuropa UomoSenior Vice PresidentOncology DevelopmentMedicinal ProductsHuman UseReceives PositiveMedicines Agency Validates Type
Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting - Vimarsana News

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

Published: November 17, 2023

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced that the companies...

Source: prnewswire.com
Related Topics:
United StatesChris BoshoffNaoki OkamuraAhsan ArozullahCourtney BuglerHead Of Oncology DevelopmentAmerican Urological Association Annual MeetingAstellas Pharma IncDrug AdministrationOncology ResearchAmerican Society Of Clinical OncologyCarolina Urologic Research CenterPfizer IncExchange CommissionEuropean UnionPrnewswire Astellas Pharma IncEuropean Medicines AgencyMedivation IncLab AbnormalitiesNew Drug ApplicationPriority ReviewFast TrackReal Time Oncology ReviewNeal ShoreChief Medical Officer
European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence - Vimarsana News

European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Published: September 12, 2023

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the European Medicines Agency (EMA) has...

Source: prnewswire.com
Related Topics:
United StatesAhsan ArozullahNaoki OkamuraMedivation IncDrug AdministrationEuropean UnionPrnewswire Astellas Pharma IncAmerican Urological Association Annual Meeting OnAmerican Society Of Clinical OncologyHead Of Oncology DevelopmentEuropean Medicines AgencyAstellas Pharma IncAstellas IncSenior Vice PresidentOncology DevelopmentUrological Association Annual MeetingPfizer Led PhaseSouth AmericaNon Metastatic Hormone Sensitive Prostate CancerHigh Risk Biochemical RecurrenceSafety InformationProduct CharacteristicsImportant Safety InformationFocus Area ApproachProstate Cancer
FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence - Vimarsana News

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Published: August 23, 2023

/PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food...

Source: prnewswire.com
Related Topics:
United StatesChris BoshoffAhsan ArozullahNaoki OkamuraPrnewswire Pfizer IncAstellas IncExchange CommissionHead Of Oncology DevelopmentAstellas Pharma IncEuropean UnionAmerican Society Of Clinical OncologyDrug AdministrationOncology ResearchLab AbnormalitiesMedivation IncAstellas PharmaPriority ReviewNew Drug ApplicationPrescription Drug User Fee ActChief Oncology ResearchDevelopment OfficerExecutive Vice PresidentSenior Vice PresidentOncology DevelopmentHazard Ratio
Neurologic Events After COVID-19 Vaccines Assessed - Vimarsana News

Neurologic Events After COVID-19 Vaccines Assessed

Published: May 26, 2023

Study finds preexisting risk factors in all patients hospitalized for neurologic symptoms

Source: medpagetoday.com
Related Topics:
New YorkUnited StatesKiran ThakurJudy GeorgeColumbia University Irving Medical Center NewyorkColumbia University Irving MedicalNewyork Presbyterian HospitalNew York CityVaccine Adverse Event Reporting SystemVaccine Safety DatalinkMedpage TodayClin Pract